Outcomes Using LVADs for Destination Therapy
Fig. 15.1 Taken from the REMATCH trial , this Kaplan-Meier analysis depicts a reduction of 48% in the risk of death from any cause (primary endpoint) in the group that…
Fig. 15.1 Taken from the REMATCH trial , this Kaplan-Meier analysis depicts a reduction of 48% in the risk of death from any cause (primary endpoint) in the group that…
Preoperative measures Risk stratification Low Moderate High Limit fluids Pulmonary vasodilators Cardiac inotropes Consider elective RVAD Operative measures Preventive High-risk patient/early RVF Fulminant RVF Limit transfusion Expeditious operative time TEE…
Fig. 12.1 CT angiogram with 3D reconstruction of left ventricular assist device. (a) Following contrast administration, filling defect can be seen along the distal portion of outflow graft. (b) Complete…
Fig. 16.1 Multimodal strategy for cardiac regeneration. Printed with permission from Baylor College of Medicine Cardiac cellular reprogramming describes the process by which cardio-differentiating (transcription) factors or the genes encoding…
Fig. 14.1 (a) Survival curves for patients who had normal albumin levels (≥3.5 g/dL), moderate hypoalbuminemia (2.5–3.5 g/dL), and severe hypoalbuminemia (<2.5 g/dL) before undergoing implantation of a continuous-flow left ventricular assist device….
Fig. 13.1 (a) The pump is exposed through an extended left subcostal incision . A self-retaining retractor is invaluable in visualizing the white silicone rubber bellows that surrounds the pump…
1. Severe symptoms of HF with dyspnea and/or fatigue at rest or with minimal exertion (NYHA functional class III or IV) 2. Episodes of fluid retention (pulmonary and/or systemic congestion,…
Fig. 6.1 The left ventricular (LV) apex is reflected in a cephalad direction to expose the diaphragmatic surface of the heart. The LV cavity is outlined by the dotted line,…